ReviewExpert opinion on emerging drugs2013
Emerging drugs for the treatment of diabetic ulcers.
Review in Expert opinion on emerging drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 56 citations in OpenAlex.
- A Randomised Controlled Clinical Study Comparing the Efficacy and Safety of an Autologous Standardised Leukocyte-Poor Platelet Gel With Standard Care for the Treatment of Chronic Neuropathic Diabetic Foot Ulcers.International wound journal · 2025Trial
- A wearable and stretchable dual-wavelength LED device for home care of chronic infected wounds.Nature communications · 2024Article
- Assessment of wound healing activity in diabetic mice treated with a novel therapeutic combination of selenium nanoparticles and platelets rich plasma.Scientific reports · 2024Article
- Understanding molecular mechanisms and miRNA-based targets in diabetes foot ulcers.Molecular biology reports · 2024Review
- Mesenchymal Stem Cell Derived Exosomes Therapy in Diabetic Wound Repair.International journal of nanomedicine · 2023Review
- Recent Advances in Nano-Drug Delivery Systems for the Treatment of Diabetic Wound Healing.International journal of nanomedicine · 2023Review
- A strain-programmed patch for the healing of diabetic wounds.Nature biomedical engineering · 2022Article
- Evolving spectrum of diabetic wound: Mechanistic insights and therapeutic targets.World journal of diabetes · 2022Review
- DPSC Products Accelerate Wound Healing in Diabetic Mice through Induction of SMAD Molecules.Cells · 2022Article
- An Overview of Diabetic Foot Ulcers and Associated Problems with Special Emphasis on Treatments with Antimicrobials.Life (Basel, Switzerland) · 2022Review
- Topical gel-based biomaterials for the treatment of diabetic foot ulcers.Acta biomaterialia · 2022Review
- Evaluation of Wound Healing Activity (Excision Wound Model) of Ointment Prepared from Infusion Extract of Polyherbal Tea Bag Formulation in Diabetes-Induced Rats.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Redox treatment ameliorates diabetes mellitus-induced skin flap necrosis via inhibiting apoptosis and promoting neoangiogenesis.Experimental biology and medicine (Maywood, N.J.) · 2021Article
- Diabetic Foot Ulcers: Current Advances in Antimicrobial Therapies and Emerging Treatments.Antibiotics (Basel, Switzerland) · 2019Review
- A Novel Gold Calreticulin Nanocomposite Based on Chitosan for Wound Healing in a Diabetic Mice Model.Nanomaterials (Basel, Switzerland) · 2019Article
- New trends in the orthopaedic management of diabetic foot.EFORT open reviews · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
introductionDiabetic ulcers are chronic nonhealing ulcerations that despite the available medical tools still result in high amputation rates. Growing evidence suggests that alteration of the biochemical milieu of the chronic wound plays a significant role in impaired diabetic wound healing. AREAS COVERED: The basic pathophysiology and the conventional treatment strategy of diabetic foot ulcers have been reviewed in the first section. In the second part, the most up-to-date bench and translational research in the field are described. The third section focuses on the drugs currently under development and the ongoing clinical trials evaluating their safety and efficacy. Finally, the major drug development issues and the possible scientific approaches to overcome them are analyzed. EXPERT OPINION: Significant strides in understanding the chronic wound development have led to the development of topical therapies to address aberrant expression of growth factors and overexpression of inflammatory cytokines. Current research in the laboratory suggests that while decreased growth factor expression occurs at the local wound level, increased systemic serum levels of growth factors suggest growth factor resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.